<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02398240</url>
  </required_header>
  <id_info>
    <org_study_id>NYMC-568</org_study_id>
    <nct_id>NCT02398240</nct_id>
  </id_info>
  <brief_title>Brentuximab for Newly Diagnosed Hodgkin Disease</brief_title>
  <official_title>A Pilot Study of Risk Adapted Therapy Utilizing Upfront Brentuximab With Combination Chemotherapy in the Treatment of Children, Adolescents and Young Adults With Newly Diagnosed Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitchell Cairo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York Medical College</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The addition of Brentuximab vedotin (Bv) to combination chemotherapy will be safe, well&#xD;
      tolerated and effective in children, adolescents and young adults with all stages of newly&#xD;
      diagnosed Hodgkin lymphoma (HL).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine if this combination of chemoimmunotherapy is safe to administer. (Adverse events)</measure>
    <time_frame>1 year</time_frame>
    <description>Adverse events will be monitored each cycle to determine if there are any events related possibly, probably or definitely related to study therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the response rate</measure>
    <time_frame>1 year</time_frame>
    <description>disease evaluations will be performed after the 2nd, 4th and 6th cycles.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Low Risk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Risk Patients (Stage IA, IIA; no bulky disease or extension): 3 cycles of chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermediate Risk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intermediate Risk Patients (Stage IA bulk/E, IB, IIA bulk/E, IIB, IIIA): 4 cycles of chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Risk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Risk Patients (Stage IIIA bulk/ E, IIIB, IVA/B): 6 cycles of chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brentuximab Vedotin</intervention_name>
    <description>Day 1 and 15 Dose: 1.2 mg/kg/dose. (Maximum dose is 120 mg)</description>
    <arm_group_label>High Risk</arm_group_label>
    <arm_group_label>Intermediate Risk</arm_group_label>
    <arm_group_label>Low Risk</arm_group_label>
    <other_name>Adcetris</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Days: 1 and 15 Dose: 25 mg/m2/dose.</description>
    <arm_group_label>High Risk</arm_group_label>
    <arm_group_label>Intermediate Risk</arm_group_label>
    <arm_group_label>Low Risk</arm_group_label>
    <other_name>Doxil, Adriamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Days: 1 and 15 Dose: 1.5 mg/m2/dose (max: 2 mg/dose).</description>
    <arm_group_label>High Risk</arm_group_label>
    <arm_group_label>Intermediate Risk</arm_group_label>
    <arm_group_label>Low Risk</arm_group_label>
    <other_name>Oncovin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Days: 2 and 16 Dose: 375 mg/m2/dose.</description>
    <arm_group_label>High Risk</arm_group_label>
    <arm_group_label>Intermediate Risk</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Normal Serum creatinine based on age or creatinine clearance &gt;60 ml/min/1.73 m2 or an&#xD;
             equivalent radioisotope glomerular filtration rate (GFR) as determined by the&#xD;
             institutional normal range.&#xD;
&#xD;
          -  Direct bilirubin &lt; 1.5 upper limit of normal (ULN) for age, and SGOT (AST) or SGPT&#xD;
             (ALT) &lt;3 x ULN&#xD;
&#xD;
          -  Shortening fraction &gt;27% by echocardiogram, or&#xD;
&#xD;
          -  Ejection fraction of &gt;50% by radionuclide angiogram or echocardiogram.&#xD;
&#xD;
          -  For patients age 1-16 years, Lansky score of ≥60.&#xD;
&#xD;
          -  For patients &gt; 16 years, Karnofsky score of ≥60.&#xD;
&#xD;
          -  No prior Hodgkin lymphoma directed therapy is allowed except for emergent mediastinal&#xD;
             irradiation (&lt;1000cGy) for superior vena cava (SVC) syndrome.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Females who are pregnant (positive HCG) or lactating.&#xD;
&#xD;
          -  Karnofsky &lt;60% or Lansky &lt;60% if less than 16 years of age.&#xD;
&#xD;
          -  Age ≤1 year or &gt;29.99 years of age.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>29 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica Hochberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Medical College</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 15, 2015</study_first_submitted>
  <study_first_submitted_qc>March 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2015</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>New York Medical College</investigator_affiliation>
    <investigator_full_name>Mitchell Cairo</investigator_full_name>
    <investigator_title>Executive Vice Chair</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Brentuximab Vedotin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

